In vitro Ceftaroline Activity against Major Bacterial Pathogens n Russia: Results of Multicenter Study

Clinical Microbiology and Antimicrobial Chemotherapy. 2015; 17(3):217-226

Type
Journal article

Background.

Ceftaroline is a new broad-spectrum cephalosporin with in vitro activity against Gram-positive pathogens, including MRSA, and common Gram-negative pathogens. It is approved for the treatment of acute complicated bacterial skin and skin-structure infections (SSSIs) and community-acquired bacterial pneumonia.

Objective.

To determine in vitro activity of ceftaroline and other clinically available antimicrobials against major bacterial pathogens from different regions of Russian Federation.

Materials and Methods.

A total of 2778 consecutive, non-duplicate isolates were collected during multicentre microbiological in vitro study from 36 geographically distinct cities of Russia during 2008–2012. Only isolates considered to be clinically significant by microbiologist or clinical practice specialist were included in the study. Among tested strains 1000 were Staphylococcus aureus (including 612 MRSA), 954 — Streptococcus pneumoniae, 338 — beta-hemolytic streptococci, 85 — Haemophilus influenzae, 401 — Enterobacteriaceae, mainly ESBL-negative strains of E.coli (n=259) and K. pneumoniae (n=50); the remaining 88 strains were represented by Citrobacter spp., Enterobacter spp., Klebsiella spp., Morganella spp., Proteus spp., Serratia spp. All the isolates were subsequently confirmed using Microflex LT MALDI Biotyper System. The isolates were stored in glycerol-supplemented tryptic soy broth (TSB) at –70 °C until analysis. Minimum inhibitory concentrations (MICs) of antimicrobials were determined by the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method.

Results.

Overall susceptibility rates to ceftaroline were 89,7% for S. aureus (100% for MSSA and 83,2% for MRSA — when using EUCAST or CLSI breakpoints; 0% for MSSA and 0,8% MRSA — when using PK/PD suggested breakpoint of ≤2 mg/l for susceptible strains), 100% for beta-hemolytic streptococci, 99,5% for S. pneumoniae, 75,8% for Enterobacteriaceae (resistant strains were mainly non-E.coli and non-K. pneumoniae AmpC-producing isolates), 98,8% — for H. influenzae.

Conclusions.

The results of the study demonstrate that ceftaroline has high in vitro activity against key bacterial pathogens and could be considered as an option for the therapy of community-acquired bacterial pneumonia and SSSIs in Russia.

Views
0 Abstract
0 PDF
0 BibTeX
Shared
0
0
0
0
0
0